Platelets and heart failure

European Heart Journal

Volumn 27, Issue 22, 2006, Pages 2623-2631

  Chung, Irene ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Antiplatelet therapy; CD40L; Heart failure; P selectin; Platelet activation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CLOPIDOGREL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NITRIC OXIDE; PROPRANOLOL; QUINAPRIL; SPIRONOLACTONE; THROMBIN; VALSARTAN; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD VISCOSITY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFECT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOGENESIS; VASCULAR RESISTANCE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PLATELET DISORDERS; CYTOKINES; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; NITRIC OXIDE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS;

EID: 33750900231     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl305     Document Type: Review

References (72)

1. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the national health service in the UK. Eur J Heart Fail 2002;4:361-371.
2. Narang R, Cleland JGF, Erhardt, Ball SG, Coats AJ, Cowley AJ, Dargie HJ, Hall AS, Hampton JR, Poole-Wilson PA. Mode of death in chronic heart failure: a request for more accurate classification. Eur Heart J 1996;17:1390-1403.
3. Lip GYH, Gibbs CR. Does heart failure confer a hypercoagulable state? J Am Coll Cardiol 1999;33:1424-1426.
4. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-164.
5. Massie B, Krol W, Ammon S, Armstrong P, Cleland J, Collins J. Warfarin and Antiplatelet therapy in Chronic Heart Failure (WATCH). http://www. acc04online.acc.org/ (9 March 2004).
6. Masoudi FA, Wolfe P, Havranek EP, Rathore SS, Foody JM, Krumholz HM. Aspirin use in older patients with heart failure and coronary artery disease. J Am Coll Cardiol 2005;46:955-962.
7. Serebruany V, McKenzie M, Meister A, Fuzaylov S, Gurbel P, Atar D, Gattis W, O'Connor C. Whole blood impedence aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial). Eur J Heart Fail 2002;4:461-467.
8. Serebruany VL, Murugesan SR, Pothula A, Atar D, Lowry DR, O'Connor CM, Gurbel PA. Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. Eur J Heart Fail 1999;1:243-249.
9. Erne P, Wradle J, Sanders K, Lewis SM, Maseri A. Mean platelet volume and size distribution and their sensitivity to agonists in patients with coronary artery disease and congestive heart failure. Thromb Haemost 1988;59:259-263.
10. Gurbel PA, Gattis WA, Fuzaylov SF, Gaulden L, Hasselblad V, Serebruany VL, O'Connor CM. Evaluation of platelets in heart failure: is platelet severity related to etiology, functional class, or clinical outcomes? Am Heart J 2002;143:1068-1075.
11. O'Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999;83:1345-1349.
12. Ueland T, Aukrust P, Yndestad A, Otterdal K, Froland SS, Dickstein K, Kjekshus J, Gullestad, Damas JK. Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 2005;26:1101-1107.
13. Serebruany VL, Alford AB, Meister AF, Fuzaylov SY, Gattis WA, Gurbel PA, O'Connor CM. Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). Thromb Res 2001;101:427-433.
14. Yin WH, Chen JW, Jen HL, Chinag MC, Huang WP, Feng AN, Lin SJ, Young MS. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic heart failure. Eur J Heart Fail 2003;5:507-516.
15. Stumpf C, Lehner C, Eska. S, Raaz D, Yilmaz A, Ropers S, Schmeisser A, Ludwig J, Daniel WG, Garlichs CD. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003;5:629-637.
16. Mehta J, Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation 1979;60:497-503.
17. Sirajuddin RA, Miller AB, Geraci SA. Anticoagulation in patients with dilated cardiomyopathy and sinus rhythm. J Card Fail 2002;8:48-53.
18. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995;25:1634-1640.
19. Jafri SM, Ozawz T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993;14:205-212.
20. Lip GY, Lowe GD, Metcalfe MJ, Rumley A, Dunn FG. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995;76:453-458.
21. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorrheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm. Circulation 2001;103:1746-1751.
22. Weiss RJ, Tobes M, Wertz CE, Smith CB. Platelet alpha2 adrenoreceptors in chronic congestive heart failure. Am J Cardiol 1983;52:101-105.
23. Badimon L, Martinez-Gonzalez J, Royo T, Lassila R, Badiomn JJ. A sudden increase in plasma epinephrine levels transiently enhance platelet deposition on severely damaged arterial wall-studies in a porcine model. Thromb Haemost 1999;82:1736-1742.
24. Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 1996;26: 353-370.
25. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 2000;11:61-69.
26. Moravec CS, Schluchter MD, Paranandi L. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation 1990;82:1973-1984.
27. Weber KT, Sun Y, Cleutjens JPM. Structural remodeling of the myocardium postinfarction: potential mechanisms and influence of therapy. Cardiol Rev 1995;3:53-65.
28. Kawano S, Kubota T, Monden Y, Kawamura N, Tsutsui H, Takeshita A, Sunagawa K. Blockade of NF-kappa B ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc Res 2005;67:689-698.
29. Sahar S, Dwarakanath RS, Reddy MA, Lanting L, Todorov I, Natarajan R. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res 2005;96:1064-1071.
30. da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, Rutledge JC, Vergona R, Sullivan ME, Wang YX. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005;178:9-17.
31. Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, Bandinelli B, Bertolozzi I, Polidori G, Toscano T, Maccherini M, Modesti PA. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Cir Res 2001;88: 961-968.
32. 2+ concentration in essential hypertension. Hypertension 1993;22:853-862.
33. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994;127:607-612.
34. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002;40:521-527.
35. Schafer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon K. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004;109:1819-1822.
36. Minamino T, Kitakaze M, Sanada S, Asanuama H, Kurotobi T, Koretsune Y. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation 1998;98:1721-1727.
37. Dixon LJ, Morgan DR, Hughes SM, McGrath LT, El-Sherbeeny NA, Plumb RD, Devine A, Leahey W, Johnston GD, McVeigh GE. Functional conquences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure. Circulation 2003;107:1725-1728.
38. - production. Thromb Haemost 2003;90:317-325.
39. Sugamori T, Ishibashi Y, Shimada T, Takahashi N, Sakane T, Ohata S, Kunizawa Y, Inoue S, Nakamura K, Ohta Y, Shimizu H, Katoh H, Oyake N, Murakami Y, Hashimoto M. Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: close correlation of tumour necrosis factor-alpha with systemic and local production of nitric oxide. Circ J 2002;66:627-632.
40. Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, Kjekshus J, Simonsen S, Froland SS, Gullestad L. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-1143.
41. Damas JK, Gullestad L, Ueland T, Solum NO, Simonsen S, Froland SS, Aukrust P. CXC-chemokines, a new group of cytokines in congestive heart failure- possible role of platelets and monocytes. Cardiovasc Res 2000;45:428-436.
42. Grose JH, Gbeassor FM, Lebel M. Differential effects of diuretics on eicosanoid biosynthesis. Postaglandins Leukat Med 1986;24:103-109.
43. Rendu F, Bachelot C, Molle D, Caen J, Guez D. Indapamide inhibits human platelet aggregation in vitro: comparison with hydrochlorothiazide. J Cardiovas Pharmacol 1993;22(Suppl. 6):S57-S63.
44. Kribben A, Fritschka E, Sibold M, Fassbender M, Rothschild M, Distler A, Philipp T. Different effects of furosemide on alpha-adrenoceptors and on platelet aggregation in man. Klin Wochschr 1988;66:624-627.
45. Gasser JA, Betterridge DJ. Comparison of the effects of carvediolol, propanolol, and verapamil on in vitro platelet function in healthy volunteers. J Cardiovasc Pharmacol 1991;18(Suppl. 4):S29-S34.
46. Knight CJ, Panesar M, Wilson DJ, Chronos NA, Patel D, Fox K, Goodall AH. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997;95:125-132.
47. Gleerup G, Mehlsen J, Winther K. Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree? J Cardiovasc Pharmacol 1995;25:87-89.
48. Gomi T, Ikeda T, Shibuya Y, Nagao R. Effects of antihypertensive treatment on platelet function in essential hypertension. Hypertens Res 2000;23:567-572.
49. Moser L, Callahan KS, Cheung AK, Stoddard GJ, Munger MA. ACE inhibitors effects on platelet function in stages I-II hypertension. J Cardiovasc Pharmacol 1997;30:461-467.
50. Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Konda K, Tanaka K. Suppressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 1984;6:840-843.
51. Persson K, Whiss PA, Nyhlen K, Jacobsson-Strier M, Glindell M, Andersson RG. Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro. Eur J Pharmacol 2000;406:15-19.
52. Keidar S, Oiknine J, Leiba A. Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients. J Cardiovasc Pharmacol 1996;27: 183-186.
53. Zurbano MJ, Anguera I, Heras M, Roig E, Lozano M, Sanz G, Escolar G. Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIIa in early postmyocardial infarction stage. Arterioscler Thromb Vasc Biol 1999;19:1791-1795.
54. Birkebaek NH, Vejby-Christensen H, Jakobsen P, Winther K. The effect of nifedipine and captopril on platelet activation and prostanoid production in essential hypertension. J Hypertens 1988;6:S378-S380.
55. Gupta RK, Kjeldsen SE, Motley E, Weder AB, Zweifler AJ, Julius S. Platelet function during antihypertensive treatment with quinalapril, a novel angiotensin converting enzyme inhibitor. J Cardiovasc Pharmacol 1991; 17:13-19.
56. Nunez A, Gomez J, Zalba LR, Monton M, Jimenez A, Velasco S, Lopez-Blaya A, Uriarte AC, Casado S, Lopez-Farre A. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000;1:175-179.
57. Schwemmer M, Sommer O, Bassenge E. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc Drugs Ther 2001;15:301-307.
58. Pathansali R, Smith NM, Bath PM. Prothrombotic megakaryocyte and platelet changes in hypertension are reversed following treatment: a pilot study. Platelets 2001;12:144-149.
59. Li-Saw-Hee FL, Beevers DG, Lip GY. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomized double-blind parallel group trial. Int J Cardiol 2001;78:241-246.
60. Li P, Fukuhara, Diz DI, Ferrario CM, Brosnihan KB. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induecd vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 2000;292:238-246.
61. Schafer A, Fraccarollo D, Hildemann S, Christ M, Eigenthaler M, Kobsar A, Walter U, Bauersachs J. Inhibition of platelet activation in congestive heart failure by aldosterone. Thromb Haemost 2003;89:1024-1030.
62. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
63. Cleland JGF, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004;6:501-508.
64. Guazzi M, Brambilla R, Reina G, Tumminello G, Guazzi MD. Aspirin-angiotensin-convering enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Arch Intern Med 2003;163:1574-1579.
65. Kindsvater S, Leclerc K, Ward J. Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Am J Cardiol 2003;91: 1350-1352.
66. Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay JF, Steinhubl SR, O'connor CM. Effects of clopidgrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 2003;146:713-720.
67. Srichai MB, Jaber WA, Prior DL, Marso SP, Houghtaling PL, Menon V, Simoons ML, Harrington RA, Hochman JS, PURSUIT Investigators. Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. Am Heart J 2004;147:84-90.
68. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK, HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006;8:428-432.
69. Lip GYH, Chung I. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst Rev 2000 doi:10.1002/14651858.CD003333.
70. Lip GYH, Chung I. Anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst Rev 2000 doi:10.1002/14651858.CD003336.
71. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U. Soluble CD40L risk prediction after acute coronary syndrome. Circulation 2003;108:1049-1052.
72. Chin BS, Blann AD, Gibbs CR, Chung NAY, Conway DS, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003;33:941-948.